Validation of an automated method for compounding monoclonal antibody patient doses

mAbs

Volumn 5, Issue 1, 2013, Pages 162-170

  Peters, Bas J M ^a   Capelle, Martinus A H ^b   Arvinte, Tudor ^b,c   Van De Garde, Ewoudt M W ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b Therapeomic Inc   (Switzerland)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Automated compounding; Bevacizumab (Avastin ); Field flow fractionation; Infliximab (Remicade ); Monoclonal antibody; Protein aggregation; Robotic compounding; Trastuzumab (Herceptin )

Indexed keywords

ANTIBODY; BEVACIZUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; ASPIRATION; AUTOMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; FEASIBILITY STUDY; FIELD FLOW FRACTIONATION; FLOW RATE; FLUORESCENCE MICROSCOPY; FLUORESCENCE SPECTROSCOPY; HUMAN; LIGHT SCATTERING; LIQUID; LYOPHILISATE; MEMBRANE RECONSTITUTION; NILE RED FLUORESCENCE MICROSCOPY; PARTICLE SIZE; POWDER; PRODUCT PARAMETERS; PROTEIN AGGREGATION; ROBOTICS; ROOM TEMPERATURE; SUMMARY OF PRODUCT CHARACTERISTICS; ULTRAVIOLET SPECTROSCOPY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOMATION; DRUG COMPOUNDING; FLOCCULATION; FRACTIONATION, FIELD FLOW; FREEZE DRYING; HUMANS; INFUSIONS, INTRAVENOUS; ROBOTICS;

EID: 84872874864     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22873     Document Type: Article

References (12)

1. Remicade Summary of Product Characteristics. Www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000240/WC500050888.pdf
2. Herceptin Summary of Product Characteristics. Www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000278/WC500074922.pdf
3. Demeule B, Palais C, Machaidze G., Gurny R, Arvinte T. New methods allowing the detection of protein aggregates: a case study on trastuzumab. MAbs 2009; 1:142-50; PMID:20061815; http://dx.doi.org/10.4161/mabs.1.2.7632
4. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure- immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21:897-903; PMID:15212151; http://dx.doi.org/10.1023/B:PHAM.0000029275.41323.a6
5. US pharmacopeia. USP/NF general chapter particulate matter in injections. in: U.S. pharmacopeia, ed. national formulary, USP29-NF-24 (suppl 2) USP; 2006
6. Cromwell ME, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J 2006; 8:E572-9; PMID:17025275; http://dx.doi.org/10.1208/ aapsj080366
7. Lowe D, Dudgeon K, Rouet R., Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011; 84:41-61; PMID:21846562; http://dx.doi.org/10. 1016/B978-0-12-386483-3.00004-5
8. Nelson AL, Dhimolea E, Reichert JM Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74; PMID:20811384; http://dx.doi.org/10.1038/nrd3229
9. Capelle MA, Brügger P, Arvinte T. Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immuno-genicity. Vaccine 2005; 23:1686-94; PMID:15705473; http://dx.doi.org/10. 1016/j.vaccine.2004.09.031
10. Demeule B, Lawrence MJ, Drake A.F., Gurny R., Arvinte T. Characterization of protein aggregation: the case of a therapeutic immunoglobulin. Biochim Biophys Acta 2007; 1774:146-53; PMID:17142116; http://dx.doi.org/10.1016/j. bbapap.2006.10.010
11. Demeule B, Gurny R, Arvinte T. Detection and characterization of protein aggregates by fluorescence microscopy. Int J Pharm 2007; 329:37-45; PMID:17005340; http://dx.doi.org/10.1016/j.ijpharm.2006.08.024
12. Palais C, Capelle M, Arvinte T. Studies of loose protein aggregates by flow field-flow fractionation (FFF) coupled to multi-angle laser light scattering (MALLS). In: Kim S, Williams R, Caldwell KD, eds. Field-Flow Fractionation in Biopolymer Analysis: Springer, 2012:103-112